GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...

Chronic kidney disease is a common complication for people living with type 2 diabetes. Diabetes is the leading cause of ...

Body weight cycling, also known as “yo-yo dieting,” is associated with a 25%-36% increased risk for diabetic kidney disease ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Chronic kidney disease (CKD) is a progressive renal disease that causes kidney function to deteriorate. It appears as urinary ...

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Chronic kidney disease has been linked to yo-yo dieting (also known as body-weight cycling) in the general population, which ...

Dialysis Centers used data from the Centers for Disease Control and Prevention to examine the prevalence of chronic diseases ...

It also reduced the risk of kidney failure and cut the risk of death from heart disease by about 5% in adults with both type 2 diabetes and chronic kidney disease, the company said in a news release.